Likewise, in the EPHESUS trial, eplerenone, a second-generation mineralocorticoid receptor antagonist, lowered hospitalization for heart failure and mortality among patients with heart failure post-myocardial infarction [20]. The gene discussed is NR3C2; the disease is heart failure.